START FREE TRIAL
Home Healthcare Biogen Inc

Biogen Inc

$19.00

SKU: BIIB Category:

Description

Biogen’s 49% Growth Portfolio Surge: Can New Products Offset MS Declines?

 

Biogen Inc. reported third quarter 2026 results showing a total revenue increase of 11% year-over-year to $2.8 billion, driven primarily by a 49% rise in its Growth Portfolio revenue to $1.26 billion, which accounted for 63% of Core Pharmaceutical revenue. This growth included contributions from the Apellis acquisition, marking its first full-quarter impact. GAAP diluted earnings per share (EPS) recorded a loss of $0.14, largely due to transaction-related charges and a significant $284 million expense related to acquired in-process research and development (IPR&D), upfront, and milestone payments primarily tied to the RayThera acquisition. On a Non-GAAP basis, diluted EPS was $2.62, down 46% from the prior year’s $4.81, influenced by the aforementioned charges. Product revenue rose 13% to $2.09 billion, with notable growth in rare disease products (27% increase) and specialized immunology (first-time contribution from Apellis products).